title: Repeated sc administration of recombinant human insulin-like growth factor I (IGF-I) to human subjects for 7 days.
abstract: Recombinant human insulin-like growth factor I (rhIGF-I) was administered subcutaneously to 6 normal subjects and 2 patients with GH deficiency at a dose of 0.1 mg/kg for 7 consecutive days after breakfast. In normal subjects, plasma IGF-I levels increased from 217 +/- 22 ng/ml (Mean +/- SEM) to maximal levels of 581 +/- 6 ng/ml 4 h after the first administration of IGF-I. The blood glucose levels were statistically depressed 4 h after injection at 69 +/- 2 mg/dl. Similar plasma IGF-I and blood glucose profiles were observed after the seventh administration of IGF-I. The free form of IGF-I in plasma was 2.3 +/- 0.3 ng/ml in normal subjects and increased to maximal levels of 43.5 +/- 5.1 ng/ml 2 h after the first IGF-I administration. A similar pattern for the free form of IGF-I was observed after the seventh administration; however, the values obtained at 0, 1 and 2 h were greater after the seventh administration. In patients with G-deficiency, the plasma IGF-I and blood glucose profiles were similar to those observed in normal subjects, although the total IGF-I levels were low in these patients at all sampling points during the study. Slight decreases in serum insulin, uric acid, and creatinine were observed after the seventh administration of IGF-I. There were no changes in the excretion of urea nitrogen, creatine, creatinine, sodium, potassium, chlorine, calcium or C-peptide in the urine during the 7 days of IGF-I administration.
authors.affiliation: Department of Medicine, Tokyo Women's Medical College, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Takano
authors.forename: N
authors.initials: N
authors.lastname: Hizuka
authors.forename: K
authors.initials: K
authors.lastname: Shizume
authors.forename: K
authors.initials: K
authors.lastname: Asakawa
authors.forename: I
authors.initials: I
authors.lastname: Fukuda
authors.forename: H
authors.initials: H
authors.lastname: Demura
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000187:drug effects*; D003404:Creatinine / Q000097:blood; D004341:Drug Evaluation; D013006:Growth Hormone / Q000172:deficiency; D006801:Humans; D007328:Insulin / Q000097:blood; D007334:Insulin-Like Growth Factor I / Q000008:administration & dosage* / Q000032:analysis / Q000627:therapeutic use; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D014527:Uric Acid / Q000097:blood
chemical_list: D001786:Blood Glucose; D007328:Insulin; D011994:Recombinant Proteins; D014527:Uric Acid; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D003404:Creatinine